Preclinical
April 17, 2023
AACR
ZW191, a novel FRα-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Lawn et al.
Preclinical
April 17, 2023
AACR
Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker
stability and the primacy of payload delivery
Colombo et al.
Preclinical
April 17, 2023
AACR
ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Hernández et al.
Preclinical
March 15, 2023 - March 16, 2023
World ADC London
ZW191: A Potential Best-in-Class TOPO1i ADC for Treatment of FRα-Expressing Solid Tumors
Sam Lawn
Preclinical
December 5, 2022
Antibody Engineering & Therapeutics Conference
Novel IgG1 Cysteine Insertion Sites Enable Site-Specific Conjugation and Precise Control of Drug to Antibody Ratio
Das et al.
Preclinical
November 10, 2022
SITC
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
October 13, 2022
Cancer Cell
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Colombo et al.
Preclinical
September 9, 2022
World ADC San Diego
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Barnscher et al.
Preclinical
May 2, 2022 - May 6, 2022
PEGS
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Petersen et al.
Preclinical
March 31, 2022
World ADC London
TOPO1i ADC Platform: From Concept to Pipeline
Preclinical
April 10, 2021
AACR
Increasing the therapeutic index of IL-12 by engineering for tumor-specific protease activation
Bishop et al.
Preclinical
April 10, 2021
AACR
ProTECT™, a novel antibody platform for integrating tumor-specific immune modulation and enhancing the therapeutic window of targeted multispecific biologics
Heinkel et al.
